[
  {
    "ts": null,
    "headline": "Gilead Sciences Inc. stock underperforms Monday when compared to competitors",
    "summary": "Gilead Sciences Inc. stock underperforms Monday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=a5eea9f44e552abfbc1b1dac8ccc3b77792aea8300ede418b831062fcb4e6966",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758558960,
      "headline": "Gilead Sciences Inc. stock underperforms Monday when compared to competitors",
      "id": 136869676,
      "image": "",
      "related": "GILD",
      "source": "MarketWatch",
      "summary": "Gilead Sciences Inc. stock underperforms Monday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=a5eea9f44e552abfbc1b1dac8ccc3b77792aea8300ede418b831062fcb4e6966"
    }
  },
  {
    "ts": null,
    "headline": "Cellares Appoints Former Kite Global Ops Leader, Christopher McDonald, to Board of Advisors",
    "summary": "SOUTH SAN FRANCISCO, Calif., September 22, 2025--Cellares, the world’s first Integrated Development and Manufacturing Organization (IDMO), today announced the appointment of Chris McDonald to its Advisory Board. McDonald most recently served as Senior Vice President and Global Head of Technical Operations (Tech Ops) at Kite, a Gilead Company, where he oversaw Global Manufacturing, Global Quality, Process Development, and Global Supply Chain across six worldwide sites and more than 3,000 employee",
    "url": "https://finnhub.io/api/news?id=f01ef91a602faee25b69fa5b86e26762cfaa56ccbd0e0fe444607415f281ac16",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758546000,
      "headline": "Cellares Appoints Former Kite Global Ops Leader, Christopher McDonald, to Board of Advisors",
      "id": 136843828,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "SOUTH SAN FRANCISCO, Calif., September 22, 2025--Cellares, the world’s first Integrated Development and Manufacturing Organization (IDMO), today announced the appointment of Chris McDonald to its Advisory Board. McDonald most recently served as Senior Vice President and Global Head of Technical Operations (Tech Ops) at Kite, a Gilead Company, where he oversaw Global Manufacturing, Global Quality, Process Development, and Global Supply Chain across six worldwide sites and more than 3,000 employee",
      "url": "https://finnhub.io/api/news?id=f01ef91a602faee25b69fa5b86e26762cfaa56ccbd0e0fe444607415f281ac16"
    }
  },
  {
    "ts": null,
    "headline": "Ensoma Announces $53 Million Financing to Support Key Clinical Milestones for EN-374 and Continued Development of In Vivo Hematopoietic Stem Cell Engineering Pipeline",
    "summary": "BOSTON, September 22, 2025--Ensoma, an in vivo hematopoietic stem cell (HSC) engineering company with a mission to advance the future of medicine through one-time therapies, today announced the closing of a $53 million financing from its existing syndicate of top-tier investors. The financing will support Ensoma’s recently initiated Phase 1/2 clinical trial for EN-374 in X-linked chronic granulomatous disease (X-CGD) and support key clinical readouts, while continuing to expand and refine the po",
    "url": "https://finnhub.io/api/news?id=c544761c814ff2a7edc890cefeb4aab9f13544dfc733859f5e2e3ca60569dc16",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758538800,
      "headline": "Ensoma Announces $53 Million Financing to Support Key Clinical Milestones for EN-374 and Continued Development of In Vivo Hematopoietic Stem Cell Engineering Pipeline",
      "id": 136850952,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "BOSTON, September 22, 2025--Ensoma, an in vivo hematopoietic stem cell (HSC) engineering company with a mission to advance the future of medicine through one-time therapies, today announced the closing of a $53 million financing from its existing syndicate of top-tier investors. The financing will support Ensoma’s recently initiated Phase 1/2 clinical trial for EN-374 in X-linked chronic granulomatous disease (X-CGD) and support key clinical readouts, while continuing to expand and refine the po",
      "url": "https://finnhub.io/api/news?id=c544761c814ff2a7edc890cefeb4aab9f13544dfc733859f5e2e3ca60569dc16"
    }
  },
  {
    "ts": null,
    "headline": "Did Gilead's (GILD) $32 Billion AI Bet Just Transform Its Innovation and Global Health Narrative?",
    "summary": "Gilead Sciences recently broke ground on a 180,000-square-foot AI-enabled Pharmaceutical Development and Manufacturing Technical Development Center at its Foster City campus, part of a US$32 billion investment plan through 2030, and expanded efforts to deliver HIV prevention therapies in partnership with PEPFAR to underserved countries. This move highlights Gilead's increasing focus on innovation and advanced technology to accelerate biologics production while reinforcing its commitment to...",
    "url": "https://finnhub.io/api/news?id=20518037215788a5a1762924de2eaf211edd58d49b006021be15e5a9ff16229f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758536867,
      "headline": "Did Gilead's (GILD) $32 Billion AI Bet Just Transform Its Innovation and Global Health Narrative?",
      "id": 136850953,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences recently broke ground on a 180,000-square-foot AI-enabled Pharmaceutical Development and Manufacturing Technical Development Center at its Foster City campus, part of a US$32 billion investment plan through 2030, and expanded efforts to deliver HIV prevention therapies in partnership with PEPFAR to underserved countries. This move highlights Gilead's increasing focus on innovation and advanced technology to accelerate biologics production while reinforcing its commitment to...",
      "url": "https://finnhub.io/api/news?id=20518037215788a5a1762924de2eaf211edd58d49b006021be15e5a9ff16229f"
    }
  }
]